09 Apr 2026

RACGP Grants and CPD Open for Applications

The RACGP is inviting applications for the 2027 Education Research Grants, supporting projects that improve GP training.

09 Apr 2026

TGA Considers Removing Herbal Ingredient Andrographis from Cold and Flu Products

The Therapeutic Goods Administration (TGA) is set to review the use of Andrographis, a herbal ingredient commonly found in cold and flu products.

09 Apr 2026

GP Hub Hits Milestone in Supporting Eating Disorder Care

A new tool helping GPs care for people with eating disorders has now been used by more than 3,500 GPs, roughly 9% of the Australian GP workforce. The milestone highlights strong demand for practical, evidence-based resources in general practice.

09 Apr 2026

New Findings Show Antidepressant May Help Reduce Methamphetamine Use

Researchers in Australia say a common antidepressant might help people cut back on methamphetamine use.

09 Apr 2026

Stay Safe This April – Updated Falls Prevention Guidelines

April is No Falls Month, a campaign to help older Australians avoid falls and injuries.

08 Apr 2026

GPs Wanted: Share Your Views in the Health of the Nation Survey

The Royal Australian College of General Practitioners is inviting GPs across Australia to share their views in the 2026 Health of the Nation survey.

08 Apr 2026

TGA Seeks Feedback on Removing Andrographis from Low-Risk Medicines List

The Therapeutic Goods Administration (TGA) has started a consultation on whether to remove Andrographis paniculata from the list of low-risk ingredients used in listed medicines.

08 Apr 2026

Australia Launches First Clinical Guideline for Youth Acute Mental Health

For the first time in Australia, new clinical guidelines have been released to help GPs and other healthcare providers manage young people experiencing mental health crises.

08 Apr 2026

NSW Measles Alert: Check Your Vaccinations

NSW Health has confirmed a measles case in Sydney and Newcastle.

08 Apr 2026

Lamotrigine Recommended for PBS Listing in Bipolar Treatment

The Pharmaceutical Benefits Advisory Committee has recommended adding lamotrigine to the Pharmaceutical Benefits Scheme as a restricted benefit for treating bipolar disorder.